Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Background: International variation in anemia assessment and management practices in chronic kidney disease (CKD) is poorly understood. Methods: We performed a cross-sectional analysis of anemia laboratory monitoring, prevalence and management in the prospective Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps). A total of 6766 participants with CKD Stages 3a–5ND from nephrology clinics in Brazil, France, Germany and the USA were included. Results: Among patients with anemia (hemoglobin <12 g/dL), 36–58% in Brazil, the USA and Germany had repeat hemoglobin measured and 40–61% had iron indices measured within 3 months of the index hemoglobin measurement. Anemia was more common in the USA and Brazil than in France and Germany across CKD stages. Higher ferritin and lower iron saturation (TSAT) levels were observed with lower hemoglobin levels, and higher ferritin with more advanced CKD. The proportion of anemic patients with ferritin <100 ng/mL or TSAT <20% ranged from 42% in Brazil to 53% in France and Germany, and of these patients, over 40% in Brazil, Germany and the USA, compared with 27% in France, were treated with oral or intravenous iron within 3 months after hemoglobin measurement. The proportion of patients with hemoglobin <10 g/dL treated with erythropoiesis-stimulating agents ranged from 28% in the USA to 57% in Germany. Conclusions: Hemoglobin and iron stores are measured less frequently than per guidelines. Among all regions, there was a substantial proportion of anemic patients with iron deficiency who were not treated with iron, highlighting an area for practice improvement in CKD care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIGURE 1 Cumulative incidence of hemoglobin measurement. (a) By CKD stage. (b) By hemoglobin level. Graph by CKD stage allows patients to contribute once for each stage. French data are excluded from the graph as the laboratory measurements are collected according to a predefined study protocol. Time 0 is the first hemoglobin (Hgb) measurement. KDIGO 2012 anemia guidelines [21]: (i) for nondialysis CKD patients with anemia not being treated with an ESA, hemoglobin should be measured when clinically indicated and at least every 3 months in patients with CKD Stages 3–5ND; (ii) for nondialysis CKD patients being treated with an ESA, hemoglobin should be measured at least monthly during the initiation phase of ESA therapy, whereas hemoglobin should be measured at least every 3 months during the maintenance phase of ESA therapy.](https://figures.cochat.ai/paper-figures/7b6f0ec1331e4ecb950697fcbf51caa8/anemia-and-iron-deficiency-among-chronic-kidney-disease-stages-35nd-patients-in-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of anemia has been linked to an unfavorable clinical course of many diseases, including infections or inflammatory disorders [12,13,14,15,16].”
From Prevalence and Predictive Value of Anemia and Dysregulated Iron Homeostasis in Patients with COVID-19 Infection (2020) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762 · cited 1×
“With respect to patient-reported outcomes (PROs), improved quality of life and fatigue scores were observed in the higher hemoglobin target group in the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta Trial (CREATE) [44] and Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) t…”
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096 · cited 1×
“With respect to patient-reported outcomes (PROs), improved quality of life and fatigue scores were observed in the higher hemoglobin target group in the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta Trial (CREATE) [44] and Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) t…”
Kalantar-Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000455387 · Cited by 1,148
Babitt, J. L., & Lin, H. Y. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111078 · Cited by 1,041 · cited 1×
“Several mechanisms of CKD-related anemia have been implicated [5], including relative erythropoietin deficiency [7], decreased red cell life span [8], abnormal iron metabolism [9], chronic inflammation [10], metabolic abnormalities [11–16] and effects of medications such as renin angiotensin system (RAS) inhibitors [1…”
BackgroundAstor, B. C., Muntner, P., Levin, A., Eustace, J. A., & Coresh, J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.12.1401 · Cited by 716
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
Macdougall, I. C., Bircher, A. J., Eckardt, K.-U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 482 · cited 1×
“tion to its gastrointestinal side effects, oral iron may not be effectively absorbed in the setting of high hepcidin levels, which are associated with inflammation [35].”
BackgroundSelf-citationTiming of Onset of CKD-Related Metabolic Complications
Moranne, O., Froissart, M., Rossert, J., Gauci, C., Boffa, J.-J., Haymann, J. P., M’rad, M. B., Jacquot, C., Houillier, P., Stengel, B., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008020159 · Cited by 478
Self-citationThe prevalence of anemia in patients with chronic kidney disease
McClellan, W., Aronoff, S. L., Bolton, W. K., Hood, S., Lorber, D. L., Tang, K. L., Tse, T. F., Wasserman, B., & Leiserowitz, M. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2763 · Cited by 474
Locatelli, F., Bárány, P., Covic, A., De Francisco, A., Del Vecchio, L., Goldsmith, D., Hörl, W., London, G., Vanholder, R., Van Biesen, W., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft033 · Cited by 471 · cited 3×
“Among Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps) countries, the Kidney Disease: Improving Global Outcomes (KDIGO) anemia guidelines [22] are widely utilized in Brazil and the USA, while the European Renal Best Practice (ERBP) group published a position statement adapting KDIGO anemia recomme…”
BackgroundInfluentialSelf-citationKDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease
Woo, K. T., & Chan, C. M. (2011) · Kidney International · doi:10.1038/ki.2011.202 · Cited by 412
Renal handling of calcium and phosphate during mineralocorticoid “escape” in man
Rastegar, A., Agus, Z., Connor, T. B., & Goldberg, M. (1972) · Kidney International · doi:10.1038/ki.1972.107 · Cited by 397
Rao, D. S., Shih, M.-S., & Mohini, R. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280304 · Cited by 390
Worldwide, mortality risk is high soon after initiation of hemodialysis
Robinson, B. M., Zhang, J., Morgenstern, H., Bradbury, B. D., Ng, L. J., McCullough, K. P., Gillespie, B. W., Hakim, R., Rayner, H., Fort, J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.252 · Cited by 347 · cited 1×
“It is probable that earlier treatment would limit the rapid worsening of anemia seen in the period prior to dialysis start, and plausible that this may be one part of a multifaceted strategy to lower the excessively high mortality that characterizes the early dialysis period [48, 49].”
BackgroundSelf-citationAzizi, M., Rousseau, A., Ezan, E., Guyene, T. T., Michelet, S., Grognet, J. M., Lenfant, M., Corvol, P., & Ménard, J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118484 · Cited by 339
Macdougall, I. C., Bock, A. H., Carrera, F., Eckardt, K.-U., Gaillard, C., Van Wyck, D., Roubert, B., Nolen, J. G., Roger, S. D., & on behalf of the FIND-CKD Study Investigators (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu201 · Cited by 328
Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency
McGonigle, R. J. S., Wallin, J. D., Shadduck, R. K., & Fisher, J. W. (1984) · Kidney International · doi:10.1038/ki.1984.36 · Cited by 288 · cited 1×
“Several mechanisms of CKD-related anemia have been implicated [5], including relative erythropoietin deficiency [7], decreased red cell life span [8], abnormal iron metabolism [9], chronic inflammation [10], metabolic abnormalities [11–16] and effects of medications such as renin angiotensin system (RAS) inhibitors [1…”
BackgroundKDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
Kliger, A. S., Foley, R. N., Goldfarb, D. S., Goldstein, S. L., Johansen, K., Singh, A., & Szczech, L. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.06.008 · Cited by 270
Angiotensin II stimulates proliferation of normal early erythroid progenitors.
Mrug, M., Stopka, T., Julian, B. A., Prchal, J. F., & Prchal, J. T. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119769 · Cited by 268
2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease
Yamamoto, H., Nishi, S., Tomo, T., Masakane, I., Saito, K., Nangaku, M., Hattori, M., Suzuki, T., Morita, S., Ashida, A., et al. (2017) · Renal Replacement Therapy · doi:10.1186/s41100-017-0114-y · Cited by 252
Molecular Mechanisms of Hepcidin Regulation: Implications for the Anemia of CKD
Babitt, J. L., & Lin, H. Y. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.12.030 · Cited by 235 · cited 1×
“Several mechanisms of CKD-related anemia have been implicated [5], including relative erythropoietin deficiency [7], decreased red cell life span [8], abnormal iron metabolism [9], chronic inflammation [10], metabolic abnormalities [11–16] and effects of medications such as renin angiotensin system (RAS) inhibitors [1…”
BackgroundEffect of parathyroid hormone on erythropoiesis.
Meytes, D., Bogin, E., Ma, A., Dukes, P. P., & Massry, S. G. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110154 · Cited by 232
Astor, B. C., Coresh, J., Heiss, G., Pettitt, D., & Sarnak, M. J. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.03.055 · Cited by 214
A randomized trial of intravenous and oral iron in chronic kidney disease
Agarwal, R., Kusek, J. W., & Pappas, M. K. (2015) · Kidney International · doi:10.1038/ki.2015.163 · Cited by 200
Kalantar-Zadeh, K., Kalantar-Zadeh, K., & Lee, G. H. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01390406 · Cited by 189 · cited 1×
“These findings are supportive of previous studies suggesting that TSAT <20% is more sensitive than ferritin <100 ng/ mL for iron deficiency in advanced CKD [33, 34].”
ResultEffect of Parathyroid Hormone on Osmotic Fragility of Human Erythrocytes
Bogin, E., Massry, S. G., Levi, J., Djaldeti, M., Bristol, G., & Smith, J. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110505 · Cited by 184
Fishbane, S., Pollack, S., Feldman, H. I., & Joffe, M. M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01670408 · Cited by 181
Icardi, A., Paoletti, E., De Nicola, L., Mazzaferro, S., Russo, R., & Cozzolino, M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft021 · Cited by 158
Vitamin D deficiency and anemia in early chronic kidney disease
Patel, N. M., Gutiérrez, O. M., Andress, D. L., Coyne, D. W., Levin, A., & Wolf, M. S. (2010) · Kidney International · doi:10.1038/ki.2009.551 · Cited by 144
The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study
Stengel, B., Combe, C., Jacquelinet, C., Briançon, S., Fouque, D. P., Laville, M., Frimat, L., Pascal, C., Herpe, Y.-É., Deleuze, J.-F., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft388 · Cited by 142 · cited 1×
“73 m(2); study methods have been previously published [29, 30].”
MethodSelf-citationvan der Meer, P., Lipsic, E., Westenbrink, B. D., van de Wal, R. M. A., Schoemaker, R. G., Vellenga, E., van Veldhuisen, D. J., Voors, A. A., & van Gilst, W. H. (2005) · Circulation · doi:10.1161/circulationaha.105.549121 · Cited by 141
PRE-dialysis survey on anaemia management
Valderrábano, F. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/18.1.89 · Cited by 123 · cited 2×
“The international PRE-dialysis Survey on Anemia Management [40] and a recent US study of Medicare and commercially insured patients report that 13 and 7% of older CKD”
MethodFerric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD
Umanath, K., Jalal, D. I., Greco, B., Umeukeje, E. M., Reisin, E., Manley, J., Zeig, S., Negoi, D., Hiremath, A. N., Blumenthal, S. S., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014080842 · Cited by 122 · cited 1×
“This analysis did not assess use of new ironbased phosphate binders such as ferric citrate [38, 39].”
BackgroundPratt, M. C., Lewis‐Barned, N., Walker, R., Bailey, R., Shand, B., & Livesey, J. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb05644.x · Cited by 115
Rambod, M., Kovesdy, C. P., & Kalantar-Zadeh, K. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01070308 · Cited by 111 · cited 1×
“Several mechanisms of CKD-related anemia have been implicated [5], including relative erythropoietin deficiency [7], decreased red cell life span [8], abnormal iron metabolism [9], chronic inflammation [10], metabolic abnormalities [11–16] and effects of medications such as renin angiotensin system (RAS) inhibitors [1…”
BackgroundStancu, S. H., Stanciu, A., Zugravu, A. D., Bârsan, L., Dumitru, D., Lipan, M., & Mircescu, G. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.10.043 · Cited by 89
Morrone, L., Paolo, S. D., Logoluso, F. A., Schena, A., Stallone, G., Giorgino, F., & Schena, F. (1997) · Transplantation · doi:10.1097/00007890-199709270-00021 · Cited by 81
Iimori, S., Naito, S., Noda, Y., Nishida, H., Kihira, H., Yui, N., Okado, T., Sasaki, S., Uchida, S., & Rai, T. (2015) · Nephrology · doi:10.1111/nep.12493 · Cited by 78 · cited 1×
“using different methods and study samples [6, 31].”
The CKD Outcomes and Practice Patterns Study (CKDopps): Rationale and Methods
Mariani, L. H., Stengel, B., Combe, C., Massy, Z. A., Reichel, H., Fliser, D., Pecoits‐Filho, R., Lopes, A. A., Yamagata, K., Wada, T., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.03.414 · Cited by 73 · cited 2×
“73 m(2); study methods have been previously published [29, 30].”
BackgroundMethodSelf-citationPeter, W. L. S., Guo, H., Kabadi, S., Gilbertson, D. T., Peng, Y., Pendergraft, T. B., & Li, S. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0861-1 · Cited by 71 · cited 1×
“patients were treated with ESAs and IV iron, respectively [41].”
Tran, L. U. P., Batech, M., Rhee, C. M., Streja, E., Kalantar‐Zadeh, K., Jacobsen, S. J., & Sim, J. J. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv297 · Cited by 46
Sato, Y., Mizuguchi, T., Shigenaga, S., Yoshikawa, E., Chujo, K., Minakuchi, J., & Kawashima, S. (2012) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2012.01089.x · Cited by 44 · cited 1×
“Several mechanisms of CKD-related anemia have been implicated [5], including relative erythropoietin deficiency [7], decreased red cell life span [8], abnormal iron metabolism [9], chronic inflammation [10], metabolic abnormalities [11–16] and effects of medications such as renin angiotensin system (RAS) inhibitors [1…”
BackgroundIron-based phosphate binders: do they offer advantages over currently available phosphate binders?
Negri, A. L., & Ureña, P. (2014) · Clinical Kidney Journal · doi:10.1093/ckj/sfu139 · Cited by 37 · cited 1×
“This analysis did not assess use of new ironbased phosphate binders such as ferric citrate [38, 39].”
BackgroundIron Therapy Challenges for the Treatment of Nondialysis CKD Patients
Locatelli, F., Mazzaferro, S., & Yee, J. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00080116 · Cited by 28 · cited 1×
“As a result, most guidelines recommend a hemoglobin target range of 10– 12 g/dL [47].”
BackgroundA 3-Marker Index Improves the Identification of Iron Disorders in CKD Anaemia
Mercadal, L., Metzger, M., Haymann, J., Thervet, É., Boffa, J., Flamant, M., Vrtovsnik, F., Gauci, C., Froissart, M., Stengel, B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084144 · Cited by 25
Self-citationWong, M. M., Tu, C., Zepel, L., Combe, C., Lopes, A. A., Pecoits‐Filho, R., Pisoni, R. L., Port, F. K., Reichel, H., Robinson, B. M., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw123.05 · Cited by 6
Self-citationMatos, C. M., Silva, L. F., Melo, N. D., Kuwano, A. Y., Kuwano, A. N., Azul, P. S., Barros, L. L., Pisoni, R. L., & Lopes, A. A. (2013) · The International Journal of Artificial Organs · doi:10.5301/ijao.5000204 · Cited by 5
Self-citation
Research works printed but not linked: 2
- Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279– 335
- World Health Organization. Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia. In: de Benoist B, McLean E, Egli Iet al (eds). Geneva: WHO Press, World Health Organization, 2008
Cited by
Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642296 · Cited by 369
Bellmann-Weiler, R., Lanser, L., Barket, R., Rangger, L., Schapfl, A., Schaber, M., Fritsche, G., Wöll, E., & Weiss, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082429 · Cited by 244
Babitt, J. L., Eisenga, M. F., Haase, V. H., Kshirsagar, A. V., Levin, A., Locatelli, F., Małyszko, J., Swinkels, D. W., Tarng, D.-C., Cheung, M., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.020 · Cited by 215
Self-citationFishbane, S., El-Shahawy, M. A., Pecoits-Filho, R., Van, B. P., Houser, M. T., Frison, L., Little, D. J., Guzman, N. J., & Pergola, P. E. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020081150 · Cited by 184
Self-citationBarratt, J., Andrić, B., Tataradze, A., Schömig, M., Reusch, M., Valluri, U., & Mariat, C. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab191 · Cited by 157
Metadata
- Authors
- Wong, M. M. Y., Tu, C., Li, Y., Perlman, R. L., Pecoits-Filho, R., Lopes, A. A., Narita, I., Reichel, H., Port, F. K., Sukul, N., Stengel, B., Robinson, B. M., Massy, Z. A., Pisoni, R. L., the CKDopps Investigators, Combe, C., Jacquelinet, C., Ayav, C., Briançon, S., Fouque, D., Frimat, L., Laville, M., Pascal, C., Herpe, Y.-E., Lange, C., Legrans, K., Liabeuf, S., Metzger, M., Speyer, E., Combe, C., Jacquelinet, C., Ayav, C., Briançon, S., Fouque, D., Frimat, L., Laville, M., Pascal, C., Herpe, Y.-E., Lange, C., Legrans, K., Liabeuf, S., Metzger, M., & Speyer, E.
- Affiliations
- University of British Columbia (CA)
- Arbor Research Collaborative for Health (US)
- University of Michigan (US)
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada
- Universidade Federal da Bahia (BR)
- Niigata University (JP)
- Nephrologisches Zentrum Villingen-Schwenningen (DE)
- CESP, Center for Research in Epidemiology and Population Health, Univ Paris-Saclay, Univ Paris-Sud, UVSQ, Inserm UMRS 1018, Villejuif, France
- Inserm (FR)
- Corresponding author
- Wong, Michelle M Y
- Venue
- Clinical Kidney Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-08-03
- Volume
- 13
- Issue
- 4
- Pages
- 613-624
- ISSN
- 2048-8505 (ISSN-L)
- 2048-8513
- PMC
- PMC7467578
- OpenAlex
- W2964863420
- Cited by
- 140
- References
- 49
- Citations by year
- 2026: 20 · 2025: 24 · 2024: 18 · 2023: 19 · 2022: 20 · 2021: 22 · 2020: 16 · 2019: 1
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Kidney Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- DOPPS Programs
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- anemia of chronic kidney disease, iron deficiency, hemoglobin monitoring, ferritin, transferrin saturation, iron supplementation, erythropoiesis-stimulating agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.